↓ Skip to main content

Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04

Overview of attention for article published in Frontiers in Public Health, June 2023
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
15 Mendeley